NYSE: BAX · Medical Instruments & Supplies
Baxter International (BAX) fair value: undervalued or overvalued?
As of 14 Nov 2026, Faircurve's model values Baxter International (BAX) at $24.84 a share. The stock last closed at $25.54, which puts the model's fair value 2.7% below the price. On the model's bands that reads as Fairly valued.
Revalued . Price is the close of 16 Nov 2026. Baxter International Inc.
The report adds the live price, the chart against the range the options market prices, the next earnings date and the analysts' consensus. No account needed.
This week, in three parts
What happenedThe run of 14 Nov 2026 held the fair value at $24.84, within 1% of the run of 7 Nov 2026.
What the model makes of itThe price of $25.54 is 2.7% above it: Fairly valued, on a medium evidence grade.
What's nextNext report on 11 Feb 2027. Options prices imply a move of about 11% either way over the next month. The next weekly run is on Saturday 21 Nov 2026.
What price range does the model give BAX?
The calibrated range for BAX over 63 trading days is $22.65 to $28.98. It sits around the last close, and its width comes from the volatility that BAX's own options imply (36% a year), calibrated weekly against realised prices (n = 8,038 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon. The fair value is the model's opinion and rides beside the range. It is not the centre of it.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $14.76 to $37.92. In 47% of the simulations the fair value came out above the price the model ran on.
Faircurve Insights · 14 Nov 2026
Baxter International Inc. is a leading developer and provider of a wide spectrum of healthcare products. It operates globally via its subsidiaries.
Faircurve's model gives Baxter a fair value of $24.84 a share on 14 Nov 2026, the midpoint of 2,000 simulations. The previous run, on 7 Nov 2026, gave the same figure. The calibrated range over 63 trading days runs from $22.57 to $29.71. It is built around the price from the volatility the stock's own options imply, and calibrated weekly against realised prices from 8,038 past valuations, refreshed 14 Nov 2026. Ranges built this way held the price 60% of the time at this horizon. The model grades the evidence Medium. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say whether the fair value is right.
Baxter's overall quality score is 26 out of 100, a composite of six factors scored against comparable companies. Earnings quality scores 86. Profitability scores 0, with ROIC at -1.7% against a peer median of 10.2%. The balance sheet scores 7, with net debt to EBITDA at 8.52x against a peer median of 0.66x. The model compares Baxter with The Cooper Companies, Solventum, Repligen, Avantor, AptarGroup, Teleflex, West Pharmaceutical Services and ResMed.
Written from the figures on this page for the 14 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.
The Global Pulse
Faircurve's note after each US session, in your inbox. No account needed.
When does BAX report earnings, and how has the stock reacted?
Baxter International's next earnings report is scheduled for 11 Feb 2027. Companies can move their dates.
Options prices on 16 Nov 2026 imply a move of about 4.9% in either direction through the nearest expiry, about 10 days out. That is the size the market is pricing, not a direction. BAX's 30 day implied volatility works out to about 10.5% over one month.
Around its last 8 reports: what the options market priced, and what followed
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across BAX's last 8 reports, ignoring direction, was 9.7%.
What the options market has priced for a month's move in BAX
How does BAX score on business quality?
Baxter International's overall quality score is 26 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.
| Factor | Score (0 to 100) | Headline measure | Peer median |
|---|---|---|---|
| ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend. | 0 | -1.7%ROIC | 10.2% |
| Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash). | 86 | ||
| Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes. | 33 | 5.7%Revenue growth, trailing | 9.9% |
| Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks. | 21 | 0.0%Net buybacks / market value | 2.1% |
| Balance sheetNet debt to EBITDA and interest coverage. | 7 | 8.52xNet debt / EBITDA | 0.66x |
| StabilityDownside volatility of the EBITDA margin over the last five years. | 0 | 10.9 ptsEBITDA margin downside volatility, 5y | 3.5 pts |
How does BAX compare with similar companies?
The companies in medical instruments & supplies closest to Baxter International in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| COO The Cooper Companies, Inc. | $61.88 | $70.88 | +14.5% | Fairly valued |
| SOLV Solventum Corporation | $88.65 | $88.47 | -0.2% | Fairly valued |
| RGEN Repligen Corporation | $162.78 | $152.66 | -6.2% | Fairly valued |
| AVTR Avantor, Inc. | $15.32 | $20.70 | +35.1% | Undervalued |
| ATR AptarGroup, Inc. | $143.17 | $137.10 | -4.2% | Fairly valued |
| TFX Teleflex Incorporated | $157.10 | $169.00 | +7.6% | Fairly valued |
| WST West Pharmaceutical Services, Inc. | $417.80 | $372.00 | -11.0% | Fairly valued |
| RMD ResMed Inc. | $238.19 | $271.74 | +14.1% | Fairly valued |
What the comparable companies' multiples alone would give for BAX, the peer-implied price, is $22.69 a share on this run. The fair value weighs that against the company's own multiple.
All medical instruments & supplies stocks ranked by gap to fair value
Baxter International at a glance
Baxter International Inc., operating globally via its subsidiaries, is a leading developer and provider of a wide spectrum of healthcare products.
- Market value
- $13.4B
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Revenue expected, next twelve months
- $11.9B
- Consensus revenue growth, next fiscal year
- +4.3%
- Analysts with estimates
- 10
- Beta to the US market
- 0.96
- First valued by Faircurve
- 1 May 2026
At the close of 16 Nov 2026, 56.8% of the 1,085 graded US stocks the model covers traded below the model's fair value. BAX was not among them.
How the fair value is worked out: the model prices Baxter International on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 7 Nov 2026 the model's fair value for BAX was $24.85. It is unchanged at $24.84 as of 14 Nov 2026. The model revalues every stock it covers each week, and again after an earnings report.
Questions about Baxter International's valuation
Is Baxter International stock undervalued or overvalued?
On Faircurve's model, BAX reads as Fairly valued as of 14 Nov 2026. The model's fair value is $24.84 a share against a last close of $25.54, a gap of -2.7%.
What is BAX's fair value?
$24.84 a share as of 14 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $14.76 to $37.92.
What price range does the model give BAX?
$22.65 to $28.98 over 63 trading days. Ranges built this way held the price 60% of the time across 8,038 past valuations, refreshed 14 Nov 2026.
When does Baxter International report earnings next?
The next report is scheduled for 11 Feb 2027. Companies can move their dates.
How much has BAX moved on past earnings reports?
Across its last 8 reports the median two session move was 9.7%, ignoring direction. The largest was -21.7% around the report of 31 Jul 2025.
How confident is the model in this valuation?
The model's evidence grade for BAX is medium. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.
The model's own ideas on BAX
The model holds no idea open on BAX today. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on BAX with their outcomes. A free account is enough.